NEW ENGLAND JOURNAL OF MEDICINE: ADAGRASIB WITH OR WITHOUT CETUXIMAB IN COLORECTAL CANCERWITH MUTATED KRAS G12C
See Mary Crowley featured in the New England Journal of Medicine.
Archive for Publications
A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
PILOT STUDY OF COMBINATION GEMOGENOVATUCEL-T (VIGIL) AND DURVALUMAB
Gemogenovatucel-T (Vigil) is a triple-function autologous tumor cell immunotherapy which expresses granulocyte-macrophage colony-stimulating factor and decreases expression of…
PHASE 1/2 STUDY OF EPACADOSTAT IN COMBINATION WITH DURVALUMAB IN PATIENTS WITH METASTATIC SOLID TUMORS
BETA PRIME: PHASE I STUDY OF ADAPT-001 AS MONOTHERAPY
BETA PRIME, a phase I clinical trial, will study AdAPT-001, an oncolytic adenovirus that carries a TGF-β ‘trap’ +/- a checkpoint inhibitor with the ultimate objective to turn ‘cold’ tumors ‘hot’ and increase response rates.
FIRST-IN-HUMAN PHASE I/IB DOSE-FINDING STUDY OF ADAGRASIB (MRTX849) IN PATIENTS
Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRASG12C…
PHASE I OPEN-LABEL STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF DILPACIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
PHASE I STUDY OF 2- OR 3-WEEK DOSING OF TELISOTUZUMAB VEDOTIN, AN ANTIBODY–DRUG CONJUGATE TARGETING C-MET, MONOTHERAPY IN PATIENTS WITH ADVANCED NON–SMALL CELL LUNG CARCINOMA
A PHASE 1B STUDY OF TELISOTUZUMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH NSCLC
Telisotuzumab vedotin (Teliso-V) is an antic-Met–directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC…
CASE REPORT: MARKED SURVIVAL ADVANTAGE OF TWO COLORECTAL CANCER PATIENTS WITH LIVER METASTASES TREATED WITH VIGIL AND FOLFOX-6
Colorectal cancer is the third most diagnosed cancer in the United States. Five-year survival rates remain low and many patients will develop liver metastasis….